[{"id":"147008c9-b17e-4123-a459-475c325f46f7","acronym":"T-START-NR","url":"https://clinicaltrials.gov/study/NCT07470996","created_at":"2026-03-28T01:43:49.187Z","updated_at":"2026-03-28T01:43:49.187Z","phase":"","brief_title":"T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR","source_id_and_acronym":"NCT07470996 - T-START-NR","lead_sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":" | ","alterations":" ALK negative","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK negative"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 10/01/2025","start_date":" 10/01/2025","primary_txt":" Primary completion: 05/30/2029","primary_completion_date":" 05/30/2029","study_txt":" Completion: 09/30/2029","study_completion_date":" 09/30/2029","last_update_posted":"2026-03-13"},{"id":"b813594c-e262-462c-9ebd-af975b8871b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04375631","created_at":"2021-01-18T21:08:17.296Z","updated_at":"2025-02-25T13:53:16.560Z","phase":"Phase 1","brief_title":"CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia","source_id_and_acronym":"NCT04375631","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • idarubicin hydrochloride • mitoxantrone • cladribine • fludarabine IV • cyclosporin A microemulsion • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 12/03/2020","start_date":" 12/03/2020","primary_txt":" Primary completion: 02/28/2027","primary_completion_date":" 02/28/2027","study_txt":" Completion: 03/17/2027","study_completion_date":" 03/17/2027","last_update_posted":"2025-02-20"},{"id":"0841b3a2-d056-4bdc-8db6-285dc71005a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02506933","created_at":"2021-01-18T12:06:04.560Z","updated_at":"2025-02-25T14:06:51.914Z","phase":"Phase 2","brief_title":"Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant","source_id_and_acronym":"NCT02506933","lead_sponsor":"City of Hope Medical Center","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Triplex (CMV-MVA vaccine)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 11/05/2015","start_date":" 11/05/2015","primary_txt":" Primary completion: 01/25/2018","primary_completion_date":" 01/25/2018","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2025-02-17"},{"id":"21aa57fd-3489-4d2b-b37d-e3d304aa4f47","acronym":"","url":"https://clinicaltrials.gov/study/NCT04616209","created_at":"2021-01-19T20:33:34.222Z","updated_at":"2025-02-25T14:40:41.368Z","phase":"Phase 1/2","brief_title":"Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients","source_id_and_acronym":"NCT04616209","lead_sponsor":"Precision Biotech Taiwan Corp.","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PB103"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 11/15/2020","start_date":" 11/15/2020","primary_txt":" Primary completion: 12/30/2027","primary_completion_date":" 12/30/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-14"},{"id":"f18181fc-ba3a-410b-9369-091830924976","acronym":"","url":"https://clinicaltrials.gov/study/NCT05457556","created_at":"2022-09-07T16:55:34.255Z","updated_at":"2025-02-25T15:12:56.234Z","phase":"Phase 3","brief_title":"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT05457556","lead_sponsor":"Children's Oncology Group","biomarkers":" FLT3 • ABL1 • BCR • NPM1 • HLA-DRB1 • CEBPA • HLA-DQB1 • HLA-B • HLA-C","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3 • ABL1 • BCR • NPM1 • HLA-DRB1 • CEBPA • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • methotrexate • melphalan • Truxima (rituximab-abbs) • fludarabine IV • thiotepa • busulfan • Mabtas (rituximab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 435","initiation":"Initiation: 03/15/2023","start_date":" 03/15/2023","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-13"},{"id":"e91a001c-1388-4b9d-9fd5-c4bd92315a77","acronym":"","url":"https://clinicaltrials.gov/study/NCT04579523","created_at":"2021-01-18T21:51:25.345Z","updated_at":"2025-02-25T15:18:52.701Z","phase":"Phase 1","brief_title":"²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma","source_id_and_acronym":"NCT04579523","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":" | ","alterations":" Chr del(17p)","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/01/2025","start_date":" 05/01/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2025-02-12"},{"id":"2d8fede0-d3af-4a3f-8d61-856862f007e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03128034","created_at":"2021-01-18T15:24:33.202Z","updated_at":"2025-02-25T16:31:10.471Z","phase":"Phase 1/2","brief_title":"211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia","source_id_and_acronym":"NCT03128034","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus • fludarabine IV • cyclosporin A microemulsion"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 10/24/2017","start_date":" 10/24/2017","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 03/31/2029","study_completion_date":" 03/31/2029","last_update_posted":"2025-02-07"},{"id":"ac72e48c-1524-449b-acbb-64797b142680","acronym":"","url":"https://clinicaltrials.gov/study/NCT04965597","created_at":"2021-07-16T13:53:25.569Z","updated_at":"2025-02-25T16:32:32.043Z","phase":"Phase 2","brief_title":"Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)","source_id_and_acronym":"NCT04965597","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • GATA2 • HLA-B • HLA-C","pipe":" | ","alterations":" LDH elevation","tags":["HLA-DRB1 • HLA-DQB1 • GATA2 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methotrexate • fludarabine IV • busulfan • Grafapex (treosulfan) • methotrexate IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 04/19/2022","start_date":" 04/19/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-07"},{"id":"e7c4a744-912a-46be-99ad-d7bc540b1466","acronym":"","url":"https://clinicaltrials.gov/study/NCT04177004","created_at":"2021-01-18T20:22:19.514Z","updated_at":"2025-02-25T16:37:37.764Z","phase":"Phase 1","brief_title":"Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant","source_id_and_acronym":"NCT04177004","lead_sponsor":"City of Hope Medical Center","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • etoposide IV • sirolimus • Kepivance (palifermin)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 04/30/2021","start_date":" 04/30/2021","primary_txt":" Primary completion: 10/27/2025","primary_completion_date":" 10/27/2025","study_txt":" Completion: 10/27/2025","study_completion_date":" 10/27/2025","last_update_posted":"2025-02-06"},{"id":"7c4709ee-03b2-4e5b-b8af-61df0f32ed05","acronym":"NCI-2018-01788","url":"https://clinicaltrials.gov/study/NCT03670966","created_at":"2021-01-18T18:00:29.277Z","updated_at":"2025-02-25T16:44:27.913Z","phase":"Phase 1/2","brief_title":"211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT03670966 - NCI-2018-01788","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-B","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV • Iomab-B (I-131-apamistamab) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/10/2019","start_date":" 07/10/2019","primary_txt":" Primary completion: 06/28/2027","primary_completion_date":" 06/28/2027","study_txt":" Completion: 03/20/2029","study_completion_date":" 03/20/2029","last_update_posted":"2025-02-05"},{"id":"7f3a4417-d9e1-41f2-85e6-183300a2b151","acronym":"NCI-2017-01311","url":"https://clinicaltrials.gov/study/NCT03246906","created_at":"2021-01-18T16:02:34.370Z","updated_at":"2025-02-25T16:44:11.978Z","phase":"Phase 2","brief_title":"Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation","source_id_and_acronym":"NCT03246906 - NCI-2017-01311","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • cyclosporin A microemulsion • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 09/11/2017","start_date":" 09/11/2017","primary_txt":" Primary completion: 05/03/2025","primary_completion_date":" 05/03/2025","study_txt":" Completion: 05/03/2025","study_completion_date":" 05/03/2025","last_update_posted":"2025-02-05"},{"id":"91e34a00-0291-46e3-8305-1607660e8c78","acronym":"","url":"https://clinicaltrials.gov/study/NCT04994808","created_at":"2021-08-06T12:53:07.543Z","updated_at":"2025-02-25T16:45:30.587Z","phase":"Phase 2","brief_title":"Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia","source_id_and_acronym":"NCT04994808","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e clofarabine • fludarabine IV • busulfan • Grafapex (treosulfan)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 08/11/2023","start_date":" 08/11/2023","primary_txt":" Primary completion: 10/03/2026","primary_completion_date":" 10/03/2026","study_txt":" Completion: 04/03/2027","study_completion_date":" 04/03/2027","last_update_posted":"2025-02-05"},{"id":"3615e982-327f-4793-b8ff-fdb95f9f33a8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03856216","created_at":"2021-01-18T19:01:48.041Z","updated_at":"2025-02-25T16:52:26.547Z","phase":"Phase 2","brief_title":"Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation","source_id_and_acronym":"NCT03856216","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD22 • HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["CD22 • HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • methotrexate • Besponsa (inotuzumab ozogamicin) • bendamustine • melphalan • Truxima (rituximab-abbs) • fludarabine IV • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 10/28/2019","start_date":" 10/28/2019","primary_txt":" Primary completion: 03/31/2027","primary_completion_date":" 03/31/2027","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2025-02-04"},{"id":"3e6558d8-f022-4465-b340-329db64b8a39","acronym":"VBP101","url":"https://clinicaltrials.gov/study/NCT04849910","created_at":"2021-04-19T11:53:06.069Z","updated_at":"2025-02-25T17:01:02.310Z","phase":"Phase 1/2","brief_title":"Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment with Mylotarg, for Patients with CD33+ AML or MDS","source_id_and_acronym":"NCT04849910 - VBP101","lead_sponsor":"Vor Biopharma","biomarkers":" CD33 • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":" | ","alterations":" CD33 expression","tags":["CD33 • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • tremtelectogene empogeditemcel (VOR33)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/16/2021","start_date":" 12/16/2021","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-03"},{"id":"6e878a86-14bd-474e-806a-2260460e86af","acronym":"VBP301","url":"https://clinicaltrials.gov/study/NCT05984199","created_at":"2023-08-09T14:09:38.757Z","updated_at":"2025-02-25T17:02:46.628Z","phase":"Phase 1/2","brief_title":"Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant","source_id_and_acronym":"NCT05984199 - VBP301","lead_sponsor":"Vor Biopharma","biomarkers":" CD33 • HLA-DRB1","pipe":"","alterations":" ","tags":["CD33 • HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VCAR33ALLO"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/11/2023","start_date":" 12/11/2023","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2025-02-03"},{"id":"8ec351f2-1bd5-4f00-9a41-65c5a39f754f","acronym":"HTLP-ONCO","url":"https://clinicaltrials.gov/study/NCT04707300","created_at":"2021-01-19T20:51:47.092Z","updated_at":"2025-02-25T17:00:53.937Z","phase":"Phase 1/2","brief_title":"Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients with Hematologic Malignancies (HTLP-ONCO)","source_id_and_acronym":"NCT04707300 - HTLP-ONCO","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" HLA-DRB1 • CD34 • CD4 • CD7","pipe":" | ","alterations":" FLT3-ITD mutation • NPM1 mutation","tags":["HLA-DRB1 • CD34 • CD4 • CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMART 102"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 02/16/2022","start_date":" 02/16/2022","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2025-02-03"},{"id":"5cbe18a7-53bc-4741-8463-14864cc423d9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06013423","created_at":"2023-08-28T14:08:26.842Z","updated_at":"2025-02-25T17:32:18.916Z","phase":"Phase 2","brief_title":"Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases","source_id_and_acronym":"NCT06013423","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" KMT2A • HLA-DRB1 • HLA-B","pipe":" | ","alterations":" MLL rearrangement","tags":["KMT2A • HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • thiotepa • cyclosporin A microemulsion"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 07/23/2024","start_date":" 07/23/2024","primary_txt":" Primary completion: 10/31/2031","primary_completion_date":" 10/31/2031","study_txt":" Completion: 10/31/2032","study_completion_date":" 10/31/2032","last_update_posted":"2025-01-31"},{"id":"cb1a79b5-e061-4b3c-834a-601d77043b7b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02512497","created_at":"2021-01-18T12:08:16.611Z","updated_at":"2025-02-25T14:35:44.470Z","phase":"Phase 1","brief_title":"Romidepsin Maintenance After Allogeneic Stem Cell Transplantation","source_id_and_acronym":"NCT02512497","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Istodax (romidepsin) • fludarabine IV • busulfan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 12/08/2017","start_date":" 12/08/2017","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-10-29"},{"id":"b054c5a5-cdfa-4e74-80e7-19a102f97c5c","acronym":"MDS-ALLO-RISK","url":"https://clinicaltrials.gov/study/NCT02757989","created_at":"2021-01-18T13:31:18.041Z","updated_at":"2025-02-25T15:53:19.596Z","phase":"","brief_title":"Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk","source_id_and_acronym":"NCT02757989 - MDS-ALLO-RISK","lead_sponsor":"Groupe Francophone des Myelodysplasies","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"],"overall_status":"Completed","enrollment":" Enrollment 79","initiation":"Initiation: 05/31/2016","start_date":" 05/31/2016","primary_txt":" Primary completion: 06/07/2024","primary_completion_date":" 06/07/2024","study_txt":" Completion: 06/07/2024","study_completion_date":" 06/07/2024","last_update_posted":"2024-08-02"},{"id":"ccaab729-08e3-4b0f-ae17-a92ba3b288af","acronym":"","url":"https://clinicaltrials.gov/study/NCT02996773","created_at":"2021-01-18T14:44:29.668Z","updated_at":"2025-02-25T16:24:52.034Z","phase":"Phase 1","brief_title":"Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine","source_id_and_acronym":"NCT02996773","lead_sponsor":"University of Arizona","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/29/2016","start_date":" 11/29/2016","primary_txt":" Primary completion: 08/25/2025","primary_completion_date":" 08/25/2025","study_txt":" Completion: 08/25/2025","study_completion_date":" 08/25/2025","last_update_posted":"2024-07-11"},{"id":"e35957f5-29cb-4356-81dc-1e80e81723d8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04572815","created_at":"2021-01-18T21:50:01.116Z","updated_at":"2024-07-02T16:34:25.809Z","phase":"Phase 2","brief_title":"Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant","source_id_and_acronym":"NCT04572815","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"],"overall_status":"Recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 05/14/2021","start_date":" 05/14/2021","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2024-06-14"},{"id":"e6cc9c0e-185c-4f74-9f02-81357b060870","acronym":"","url":"https://clinicaltrials.gov/study/NCT03145545","created_at":"2021-01-18T15:30:11.985Z","updated_at":"2024-07-02T16:34:26.112Z","phase":"","brief_title":"Expanded Access Protocol Using Alpha/Beta T and CD19+ Depleted PBSC","source_id_and_acronym":"NCT03145545","lead_sponsor":"Children's Hospital of Philadelphia","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2024-06-14"},{"id":"ea8aa5eb-747e-43c1-9888-86c7239699c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00547196","created_at":"2021-01-18T01:59:32.370Z","updated_at":"2024-07-02T16:34:25.798Z","phase":"","brief_title":"AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies \u0026 Disorders","source_id_and_acronym":"NCT00547196","lead_sponsor":"City of Hope Medical Center","biomarkers":" KMT2A • HLA-DRB1 • HLA-B","pipe":"","alterations":" ","tags":["KMT2A • HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • busulfan • cyclosporine • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 08/16/2005","start_date":" 08/16/2005","primary_txt":" Primary completion: 11/11/2009","primary_completion_date":" 11/11/2009","study_txt":" Completion: 05/28/2024","study_completion_date":" 05/28/2024","last_update_posted":"2024-06-14"},{"id":"6cd3b965-1498-4a7b-8e52-1d5006e1cb85","acronym":"","url":"https://clinicaltrials.gov/study/NCT05322850","created_at":"2022-04-12T14:52:55.429Z","updated_at":"2024-07-02T16:34:26.410Z","phase":"Phase 1/2","brief_title":"Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)","source_id_and_acronym":"NCT05322850","lead_sponsor":"University of Florida","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e OrcaGraft (engineered donor allograft cell therapy)"],"overall_status":"Suspended","enrollment":" Enrollment 40","initiation":"Initiation: 08/16/2022","start_date":" 08/16/2022","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-06-13"}]